ABBV AbbVie, Inc.

Price (delayed)

$98.88

Market cap

$146.02B

P/E Ratio

17.44

Dividend/share

$4.5

EPS

$5.67

Enterprise value

$171.92B

Business Summary

Sector: Healthcare

Industry: Drug Manufacturers - General

Website: http://www.abbvie.com

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Highlights

The EPS has soared by 58% YoY and by 7% from the previous quarter

The company's net income has surged by 57% YoY and by 7% QoQ

Key stats

Shares outstanding

1.48B

Market cap

$146.02B

Enterprise value

$171.92B

EBIT

$10.59B

EBITDA

$12.67B

Price to earnings (P/E)

17.44

Price to book (P/B)

N/A

Price to sales (P/S)

4.3

EV/EBIT

16.23

EV/EBITDA

13.57

Net debt/EBITDA

2.05

EV/Sales

5.05

EBITDA margin

37.2%

Gross margin

77.4%

Net margin

24.8%

Operating margin

39.9%

Return on assets

11.4%

Return on equity

N/A

Return on invested capital

20.7%

Return on capital employed

14.2%

Return on sales

31.1%

Debt to equity

-9.04

Free cash flow

$13.55B

Free cash flow per share

$9.15

Book value per share

-$5.01

Revenue per share

$23

TBVPS

$38.78

Current ratio

3.14

Quick ratio

2.88

Working capital

$35.29B

Dividend yield

4.55%

DPS

$4.5

Payout ratio

79.4%

ABBV stock price

Financial performance

The operating income has soared by 109% YoY and by 4.6% from the previous quarter

The operating margin has surged by 101% year-on-year and by 2.3% since the previous quarter

The company's net income has surged by 57% YoY and by 7% QoQ

The net margin has surged by 51% year-on-year and by 4.6% since the previous quarter

Valuation

Price to earnings (P/E)

Current price to earnings (P/E):

17.44

The EPS has soared by 58% YoY and by 7% from the previous quarter

ABBV's P/E is 22% below its last 4 quarters average of 22.3 and 19% below its 5-year quarterly average of 21.4

Price to book (P/B)

Current price to book (P/B):

N/A

AbbVie Inc's equity has increased by 9% from the previous quarter and by 5% YoY

Price to sales (P/S)

Current price to sales (P/S):

4.3

ABBV's P/S is 23% above its last 4 quarters average of 3.5 and 2.4% above its 5-year quarterly average of 4.2

ABBV's revenue is up by 4.3% year-on-year and by 2.4% since the previous quarter

Efficiency

The ROS has soared by 65% YoY and by 4% from the previous quarter

AbbVie Inc's return on assets has increased by 30% YoY but it has decreased by 5% QoQ

AbbVie Inc's ROIC has increased by 29% YoY but it has decreased by 8% from the previous quarter

Dividends

DPS

$4.5

Dividend yield

4.55%

Payout ratio

79.4%

Recent dividends

Financial health

Assets vs liabilities

AbbVie Inc's total assets is 8% lower than its total liabilities

AbbVie Inc's total assets has surged by 61% YoY and by 2.3% QoQ

Debt vs equity

The company's debt to equity has shrunk by 90% YoY and by 11% QoQ

AbbVie Inc's equity has increased by 9% from the previous quarter and by 5% YoY